Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
92 hedge funds and large institutions have $227M invested in Eiger BioPharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 11 closing their positions.
146% more call options, than puts
Call options by funds: $2.22M | Put options by funds: $905K
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
21% more capital invested
Capital invested by funds: $188M → $227M (+$39M)
1% more funds holding
Funds holding: 91 → 92 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$4.42M |
| 2 |
6CM
683 Capital Management
New York
|
+$3.81M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$3.37M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.27M |
| 5 |
CA
CHI Advisors
New York
|
+$2.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$5.14M |
| 2 |
Morgan Stanley
New York
|
-$3.32M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.27M |
| 4 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$887K |
| 5 |
TI
Telemetry Investments
New York
|
-$815K |
EIGR Hedge Fund Activity: Q3 2022 in Review
92 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2022, worth a combined $227M — up 21% from $188M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new EIGR positions and 11 closed out — a net gain of 1 holder — while 36 added to existing stakes and 25 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $4.42M. The largest seller was Soleus Capital Management, cutting an estimated $5.14M.
- 92 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2022, up from 91 in Q2 2022.
- Funds reported $227M of Eiger BioPharmaceuticals, Inc. stock for Q3 2022, up 21% quarter-over-quarter.
- 12 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2022 and 11 closed out, a net change of +1 holder.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2022 was Baker Bros. Advisors, an estimated $4.42M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2022 was Soleus Capital Management, an estimated $5.14M sold.
Based on aggregated 13F filings for Q3 2022.